Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) has completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol (“CBD“) on skin hydration.
- Study was conducted by an independent research laboratory: INOVAPOTEK, Pharmaceutical Research and Development in Portugal”.
- The study aimed to assess the hydrating efficacy of the Serum in vivo, by measuring the skin capacitance for a period of 2, 4, 8 and 24 hours after the CBD Serum application on the skin.
- The results demonstrated that there were significant hydration increases for each period.
- The Serum was well tolerated with no uncomfortable symptoms or feelings reported by the subjects of the study.
In addition, the research laboratory completed a clinical controlled study for the evaluation of the acute cutaneous irritation potential of cosmetic products. All of the SHIR™ Derma Cosmetic products tested to date have demonstrated to be non-irritating under the test conditions.
Tags: CBD, CBD Derma Cosmetics, CBD stocks, CSE, Innocan, Relief & Go Pain Relief Spray, small cap, smallcap stocks, stocks, tsx